Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daclizumab + infliximab
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Daclizumab + infliximab is a combination of two monoclonal antibody drugs used as an anti-cytokine therapy, primarily investigated for the treatment of steroid-refractory graft-versus-host disease (SR-GVHD). Daclizumab is a humanized IgG1 monoclonal antibody that targets CD25, the alpha subunit of the high-affinity interleukin-2 receptor (IL-2R), thereby inhibiting IL-2-mediated activation and proliferation of T cells. Infliximab is a chimeric IgG1 monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-α), neutralizing its pro-inflammatory effects and reducing inflammation. The combination aims to suppress immune responses by targeting both IL-2 and TNF-α pathways, which are critical mediators in inflammatory and autoimmune conditions[1][7][6].
- Brand names
- RemicadeZenapax
- Other names
- infliximab and daclizumab combinationanti-cytokine combination therapy
02
Targets
IL2RA (Interleukin-2 receptor alpha subunit)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on daclizumab + infliximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daclizumab + infliximab.